Raph L Hamers

List of Publications by Year
in descending order

98 papers	4,022 citations	126858 33 h-index	128225 60 g-index
111 all docs	111 docs citations	111 times ranked	4443 citing authors

#	Article	IF	Citations
1	Perceptions, views and practices regarding antibiotic prescribing and stewardship among hospital physicians in Jakarta, Indonesia: a questionnaire-based survey. BMJ Open, 2022, 12, e054768.	0.8	6
2	Blood culture utilization and epidemiology of antimicrobial-resistant bloodstream infections before and during the COVID-19 pandemic in the Indonesian national referral hospital. Antimicrobial Resistance and Infection Control, 2022, 11, 73.	1.5	12
3	Optimizing antibiotic use in Indonesia: A systematic review and evidence synthesis to inform opportunities for intervention. , 2022, 2, 100013.		7
4	Developing a priority global research agenda for antimicrobial resistance in the human health sector: protocol for a scoping review. BMJ Open, 2022, 12, e060553.	0.8	2
5	Neurological Disease Associated with Chikungunya in Indonesia. American Journal of Tropical Medicine and Hygiene, 2022, 107, 291-295.	0.6	3
6	A qualitative study of barriers to antimicrobial stewardship in Indonesian hospitals: governance, competing interests, cost, and structural vulnerability. Antimicrobial Resistance and Infection Control, 2022, 11, .	1.5	3
7	Pandemic inequity in a megacity: a multilevel analysis of individual, community and healthcare vulnerability risks for COVID-19 mortality in Jakarta, Indonesia. BMJ Global Health, 2022, 7, e008329.	2.0	10
8	Evaluating Saliva Sampling with Reverse Transcription Loop-mediated Isothermal Amplification to Improve Access to SARS-CoV-2 Diagnosis in Low-Resource Settings. American Journal of Tropical Medicine and Hygiene, 2022, , .	0.6	0
9	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	0.9	5
10	Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. The Lancet Regional Health - Western Pacific, 2021, 9, 100108.	1.3	75
11	A multicentre point prevalence survey of patterns and quality of antibiotic prescribing in Indonesian hospitals. JAC-Antimicrobial Resistance, 2021, 3, dlab047.	0.9	18
12	2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. Journal of Antimicrobial Chemotherapy, 2021, 76, 1898-1906.	1.3	1
13	Improving host-directed therapy for tuberculous meningitis by linking clinical and multi-omics data. Tuberculosis, 2021, 128, 102085.	0.8	4
14	Surveillance strategies using routine microbiology for antimicrobial resistance in low- and middle-income countries. Clinical Microbiology and Infection, 2021, 27, 1391-1399.	2.8	20
15	Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials. Frontiers in Pharmacology, 2021, 12, 664875.	1.6	10
16	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	0.9	4
17	Transaminases and serum albumin as early predictors of severe dengue. Lancet Infectious Diseases, The, 2021, 21, 1488-1489.	4.6	1
18	Plasma Inflammatory Biomarkers Predict CD4+ T-cell Recovery and Viral Rebound in HIV-1 Infected Africans on Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 224, 673-678.	1.9	4

#	Article	IF	Citations
19	Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact. Journal of Infectious Diseases, 2020, 221, 1584-1597.	1.9	40
20	Is increasing pretreatment HIV drug resistance a real menace or minor detail?. Lancet HIV,the, 2020, 7, e316-e317.	2.1	1
21	The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. Aids, 2020, 34, 1559-1566.	1.0	11
22	Pan-resistant HIV-1: what's next?. Lancet Microbe, The, 2020, 1, e97-e98.	3.4	2
23	Global and regional epidemiology of HIV-1 recombinants in 1990â€"2015: a systematic review and global survey. Lancet HIV,the, 2020, 7, e772-e781.	2.1	51
24	The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation. PLoS ONE, 2020, 15, e0238027.	1.1	2
25	ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance. Wellcome Open Research, 2020, 5, 13.	0.9	18
26	ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance. Wellcome Open Research, 2020, 5, 13.	0.9	13
27	Title is missing!. , 2020, 15, e0238027.		0
28	Title is missing!. , 2020, 15, e0238027.		0
29	Title is missing!. , 2020, 15, e0238027.		0
30	Title is missing!. , 2020, 15, e0238027.		0
31	Title is missing!. , 2020, 15, e0238027.		0
32	Title is missing!. , 2020, 15, e0238027.		0
33	Pretreatment HIV drug resistance in low- and middle-income countries. Future Virology, 2019, 14, 427-440.	0.9	3
34	Dolutegravir for second-line antiretroviral therapy. Lancet Infectious Diseases, The, 2019, 19, 218-219.	4.6	1
35	Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. Lancet Infectious Diseases, The, 2019, 19, e246-e252.	4.6	41
36	Distinct rates and patterns of spread of the major HIV-1 subtypes in Central and East Africa. PLoS Pathogens, 2019, 15, e1007976.	2.1	37

#	Article	IF	Citations
37	What the WHO's List of Essential Diagnostics means for clinical microbiology laboratories and antimicrobial stewardship practice worldwide. Clinical Microbiology and Infection, 2019, 25, 6-9.	2.8	7
38	Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?. Clinical Infectious Diseases, 2019, 68, 2158-2160.	2.9	2
39	Global and regional molecular epidemiology of HIV-1, 1990â€"2015: a systematic review, global survey, and trend analysis. Lancet Infectious Diseases, The, 2019, 19, 143-155.	4.6	255
40	Dolutegravir in sub-Saharan Africa: context is crucial. Lancet HIV,the, 2019, 6, e72-e73.	2.1	14
41	Standardized approaches for clinical sampling and endpoint ascertainment in tuberculous meningitis studies. Wellcome Open Research, 2019, 4, 204.	0.9	5
42	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	0.9	11
43	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	0.9	6
44	Standardized approaches for clinical sampling and endpoint ascertainment in tuberculous meningitis studies. Wellcome Open Research, 2019, 4, 204.	0.9	6
45	Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. Journal of Antimicrobial Chemotherapy, 2018, 73, 1167-1172.	1.3	49
46	HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infectious Diseases, The, 2018, 18, 346-355.	4.6	290
47	Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. Aids, 2018, 32, 1043-1051.	1.0	47
48	When prevention of mother-to-child HIV transmission fails. Aids, 2018, 32, 143-147.	1.0	7
49	Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV,the, 2018, 5, e638-e646.	2.1	56
50	Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.9	14
51	HIV drug resistance in low-income and middle-income countries. Lancet HIV,the, 2018, 5, e588-e596.	2.1	59
52	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. Journal of Antimicrobial Chemotherapy, 2018, 73, 2186-2196.	1.3	4
53	Antibiotic consumption in low-income and middle-income countries. The Lancet Global Health, 2018, 6, e732.	2.9	10
54	Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.9	30

#	Article	IF	Citations
55	Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya. Aids, 2017, 31, 1495-1498.	1.0	15
56	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 2017, 18, 225-235.	2.7	28
57	Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infectious Diseases, The, 2017, 17, 296-304.	4.6	58
58	Adherence to antiretroviral therapy for HIV in sub‐Saharan Africa and Asia: a comparative analysis of two regional cohorts. Journal of the International AIDS Society, 2017, 20, 21218.	1.2	56
59	Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS ONE, 2017, 12, e0181357.	1.1	31
60	Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. Journal of Infectious Diseases, 2016, 214, 873-883.	1.9	41
61	Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. Journal of Antimicrobial Chemotherapy, 2016, 71, 2918-2927.	1.3	75
62	Next-generation sequencing and HIV drug resistance surveillance. Lancet HIV,the, 2016, 3, e553-e554.	2.1	6
63	Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infectious Diseases, The, 2016, 16, e267-e275.	4.6	54
64	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	1.3	7
65	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infectious Diseases, The, 2016, 16, 565-575.	4.6	217
66	Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk. Journal of Antimicrobial Chemotherapy, 2016, 71, 1619-1626.	1.3	13
67	Enhancement of clinical decision making in HIV care in Africa. Lancet HIV,the, 2016, 3, e59-e60.	2.1	0
68	Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study. PLoS ONE, 2016, 11, e0167492.	1.1	62
69	Pretreatment HIV Drug Resistance Increases Regimen Switches in Sub-Saharan Africa. Clinical Infectious Diseases, 2015, 61, civ656.	2.9	51
70	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 2015, 12, e1001810.	3.9	188
71	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS ONE, 2015, 10, e0145772.	1.1	72
72	Increasing the use of second‐line therapy is a cost‐effective approach to prevent the spread of drug‐resistant HIV: a mathematical modelling study. Journal of the International AIDS Society, 2014, 17, 19164.	1.2	26

#	Article	IF	Citations
73	HIV Type 1 Transmission Networks Among Men Having Sex with Men and Heterosexuals in Kenya. AIDS Research and Human Retroviruses, 2014, 30, 118-126.	0.5	34
74	An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. Journal of Antimicrobial Chemotherapy, 2014, 69, 1104-1110.	1.3	13
75	Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance. Aids, 2014, 28, 73-83.	1.0	24
76	HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa. Lancet Infectious Diseases, The, 2013, 13, 196-197.	4.6	4
77	Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Current Opinion in HIV and AIDS, 2013, 8, 19-26.	1.5	70
78	Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings. Journal of Antimicrobial Chemotherapy, 2013, 68, 1406-1414.	1.3	29
79	Short Communication: High Rates of Thymidine Analogue Mutations and Dual-Class Resistance Among HIV-Infected Ugandan Children Failing First-Line Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2013, 29, 925-930.	0.5	16
80	Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies. Clinical Infectious Diseases, 2012, 54, 1660-1669.	2.9	144
81	Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance—HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. International Journal of Epidemiology, 2012, 41, 43-54.	0.9	53
82	Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa. Aids, 2012, 26, 1663-1672.	1.0	43
83	Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infectious Diseases, The, 2012, 12, 307-317.	4.6	162
84	Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet, The, 2012, 380, 1250-1258.	6.3	324
85	Short Communication: High Prevalence of Transmitted Antiretroviral Drug Resistance Among Newly HIV Type 1 Diagnosed Adults in Mombasa, Kenya. AIDS Research and Human Retroviruses, 2012, 28, 1033-1037.	0.5	34
86	HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infectious Diseases, The, 2011, 11, 750-759.	4.6	258
87	Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 23-31.	0.9	176
88	Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. Aids, 2011, 25, 905-910.	1.0	56
89	Interaction between Antiretroviral Drugs and Acenocoumarol. Antiviral Therapy, 2011, 16, 249-252.	0.6	13
90	Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine. Antiviral Therapy, 2011, 16, 115-118.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings. Journal of Antimicrobial Chemotherapy, 2010, 65, 605-607.	1.3	22
92	Acute necrotizing pancreatitis following inadvertent extensive splenic artery embolisation for trauma. British Journal of Radiology, 2009, 82, e11-e14.	1.0	24
93	Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antiviral Therapy, 2009, 14, 619-29.	0.6	35
94	Dried Fluid Spots for HIV Type-1 Viral Load and Resistance Genotyping: A Systematic Review. Antiviral Therapy, 2009, 14, 619-629.	0.6	70
95	The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antiviral Therapy, 2008, 13, 625-39.	0.6	22
96	The Status of HIV-1 Resistance to Antiretroviral drugs in Sub-Saharan Africa. Antiviral Therapy, 2008, 13, 625-639.	0.6	36
97	Chronic obstructive pulmonary disease in Brazilian primary care: diagnostic competence and case-finding. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 299-306.	2.5	13
98	COVID-19 Social Science and Public Engagement Action Research in Vietnam, Indonesia and Nepal (SPEAR): Protocol for a mixed methods study exploring the experiences and impacts of COVID-19 for healthcare workers and vulnerable communities. Wellcome Open Research, 0, 6, 352.	0.9	2